Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Zeitz

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Ophthalmology|December 3, 2014
Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degenerationMitsuko Yuzawa, Kyoko Fujita, Kim U Wittrup-Jensen, et al.
The British Journal of Ophthalmology|January 10, 2013
VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO studyFrank G Holz, Johann Roider, Yuichiro Ogura, et al.
The EMBO Journal|February 12, 2005
Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegenerationDagmar Kasper, Rosa Planells-Cases, Jens C Fuhrmann, et al.
American Journal of Ophthalmology|July 29, 2014
Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO studyYuichiro Ogura, Johann Roider, Jean-François Korobelnik, et al.
Ophthalmology|March 24, 2012
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS studyDavid Boyer, Jeffrey Heier, David M Brown, et al.
American Journal of Ophthalmology|February 15, 2015
Reply: To PMID 25068637Yuichiro Ogura, Johann Roider, Jean-François Korobelnik, et al.
Retina (Philadelphia, Pa.)|March 2, 2022
INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized TrialDavid M Brown, David S Boyer, Karl Csaky, et al.
Ophthalmology|April 1, 2014
Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS studyJeffrey S Heier, W Lloyd Clark, David S Boyer, et al.
Movement Disorders Clinical Practice|July 7, 2020
Functionally Relevant Maculopathy and Optic Atrophy in Spinocerebellar Ataxia Type 1Frederike Cosima Oertel, Oliver Zeitz, Maria Rönnefarth, et al.
Journal of Vitreoretinal Diseases|April 3, 2023
Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized TrialJeffrey S Heier, Allen C Ho, David S Boyer, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Ophthalmology|December 3, 2014
Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degenerationMitsuko Yuzawa, Kyoko Fujita, Kim U Wittrup-Jensen, et al.
The British Journal of Ophthalmology|January 10, 2013
VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO studyFrank G Holz, Johann Roider, Yuichiro Ogura, et al.
The EMBO Journal|February 12, 2005
Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegenerationDagmar Kasper, Rosa Planells-Cases, Jens C Fuhrmann, et al.
American Journal of Ophthalmology|July 29, 2014
Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO studyYuichiro Ogura, Johann Roider, Jean-François Korobelnik, et al.
Ophthalmology|March 24, 2012
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS studyDavid Boyer, Jeffrey Heier, David M Brown, et al.
American Journal of Ophthalmology|February 15, 2015
Reply: To PMID 25068637Yuichiro Ogura, Johann Roider, Jean-François Korobelnik, et al.
Retina (Philadelphia, Pa.)|March 2, 2022
INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized TrialDavid M Brown, David S Boyer, Karl Csaky, et al.
Ophthalmology|April 1, 2014
Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS studyJeffrey S Heier, W Lloyd Clark, David S Boyer, et al.
Movement Disorders Clinical Practice|July 7, 2020
Functionally Relevant Maculopathy and Optic Atrophy in Spinocerebellar Ataxia Type 1Frederike Cosima Oertel, Oliver Zeitz, Maria Rönnefarth, et al.
Journal of Vitreoretinal Diseases|April 3, 2023
Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized TrialJeffrey S Heier, Allen C Ho, David S Boyer, et al.
Pageof 10